April 12, 2019 After completing a number of clinical trials, The MPN community was disappointed when a promising compound in development for myelofibrosis, momelotinib, was… Read More »PROMISING MF TREATMENT, MOMELOTINIB, IN DEVELOPMENT ONCE MORE
The MPN Research Foundation has invested more in Interferon research in the past few years through our MPN Interferon Initiative, a global collaboration among researchers… Read More »MPNRF’S EXECUTIVE DIRECTOR DISCUSSES THE INTERFERON INITIATIVE
Clinical trials are research programs conducted with patients to evaluate a new medical treatment, drug, or device. Clinical studies help bridge research and patient care… Read More »MPN CLINICAL TRIALS: WHAT TO EXPECT
The MPN community is discussing the article by MPN researchers from MD Anderson – Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation – a retrospective study… Read More »BLOOD ARTICLE DISCUSSES EPIGENETIC CHANGES IN MYELOFIBROSIS FOLLOWING DISCONTINUATION OF RUXOLITINIB
Parterships are Important. They bring people together in pursuit of a common cause and put many minds to work on a problem, increasing the likelihood… Read More »THE IMPORTANCE OF PARTNERSHIPS IN THE MPN COMMUNITY
The Centers for Medicare & Medicaid Services’ Coverage and Analysis Group released a proposed decision memo Thursday on modifications to the National Coverage Determination for… Read More »UPDATE ON MEDICARE COVERAGE DECISION FOR STEM CELL TRANSPLANT IN MYELOFIBROSIS
There were many interesting sections from today’s meeting. Bill Crowley from the MPN Research Foundation was on the ground at the event and shared some… Read More »NOTES FROM CR&T MPN SYMPOSIUM
Does the smiling face of Layla Richards mark a new era in genetic medicine that could change all our lives? The story of Layla Richards… Read More »IS THIS THE BEGINNING OF GENE-EDITING MEDICINE?
On October 29, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule allowing Medicare coverage for stem cell transplants in approved clinical… Read More »TAKE ACTION NOW-MEDICARE IS ABOUT TO SET STANDARDS FOR MYELOFIBROSIS RELATED STEM CELL TRANSPLANTS
According to a paper published in Nature Medicine, the drug MLN8237 (or Alisertib) has reduced tumor cells, blood counts and fibrosis in mouse models of… Read More »NATURE MEDICINE: DRUG STOPS REPRODUCTION OF CANCER CELLS IN MYELOFIBROSIS
